home / stock / canf / canf articles
Shares of AMMO, Inc. (NASDAQ:POWW) fell sharply during Friday's session following fourth-quarter results. AMMO reported a fourth-quarter profi...
Can-Fite BioPharma Ltd (NYSE: CANF) announced that a patient who participated in the Phase 2 Liver Cancer Study and was treated with namodenos...
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgr...
News, Short Squeeze, Breakout and More Instantly...
Can-Fite Biopharma Ltd Sponsored ADR Company Name:
CANF Stock Symbol:
NYSE Market:
Can-Fite Biopharma Ltd Sponsored ADR Website:
Liver cirrhosis treatment global market is estimated to reach $29.2 billion by 2030 Ramat Gan, Israel, July 01, 2024 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE:CFBI), a biotechnology company with a pipeline of proprietary small molecule drugs that addr...
The canine osteoarthritis market is projected to reach $3 billion by 2028 Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address oncological and inflammatory diseases, today announced ...
Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address oncological and inflammatory diseases, today announces that company scientists came up with breakthrough findings showing that the anti-cance...